Why the study?
Does enoximone affect the pharmacokinetics of digoxin in patients with congestive heart failure?
Does enoximone affect the pharmacokinetics of digoxin in patients with congestive heart failure?
Concomitant administration of enoximone does not alter digoxin pharmacokinetics in patients with heart failure, while improving hemodynamics.
Answers are grounded in this paper and cite their sources.
Supports safe coadministration without digoxin interaction in heart failure; hypothesis-generating pending randomized confirmation.
The aim of this study was to investigate if the concomitant administration of the positive inotropic drug enoximone (100 mg tid) has any effect on the morning through levels of the cardiac glycoside digoxin in 17 patients with congestive heart failure (NYHA II-IV). Plasma concentrations of digoxin were 1.05 +/- 0.37 ng/mL before enoximone, 0.95 +/- 0.31 ng/mL at the end of the enoximone treatment period of 1 week and 0.95 +/- 0.36 ng/mL 1 week after cessation of enoximone treatment. Thus, concomitant administration of enoximone had no effect on plasma concentrations of digoxin while on the other hand the hemodynamics as assessed by NYHA-classification and determination of the heart volume improved significantly.
No takes yet. Share an insight, caveat, or question.
Trenk et al. (1990) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: